Page 5 - Published May News Today

V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal on statin therapy alone led to significant LDL-C reduction vs. clinician-determined usual care (60% vs. 7% respectively)1 A significantly greater proportion of the ASCVD patients receiving Leqvio achieved guideline-recommended LDL-C goal vs. the usual care arm […]

V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal...

V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal on...

The submission could grant guselkumab its third indication, after being approved by the FDA for psoriasis and psoriatic arthritis.

Language barriers between pharmacists and patients impacts medication adherence, patient education, and overall health outcomes, resulting in patient harm.

A selection of non-fiction titles that are already generating buzz.

As the years comes to an end, The News-Review looks at the favorite and most popular education stories of 2023.

Here are the stories that captured your attention in 2023 from NPR.org and across the NPR Network.

Here are the stories that captured your attention in 2023 from NPR.org and across the NPR Network.

The Contemporary Pediatrics Editor-in-Chief reviews the pharmacological breakthroughs and epidemiological setbacks that defined RSV in 2023.